Calcium-regulating peptide hormone

Calcitonin

Calcitonin: the app lists a half-life of 1 hour, and the Miacalcin label gives the terminal half-life of calcitonin salmon as 59 to 64 minutes after subcutaneous injection.1

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Calcitonin after one dose: 50% at ~1 h, 25% at 2 h, 12.5% at 3 h.

Drawn from the half-life in the app's model, ~1 h. The model's figures

Half-life ~1 h Reported in the sources For human calcitonin given by intravenous infusion to eight healthy subjects, elimination was biphasic, with half-lives of 10.2 and 37.8 minutes (Antonin and colleagues, 1992).5 Other records retrieved for human calcitonin report clearance: metabolic clearance rates of 531 to 1224 litres/day on infusion in 12 normal subjects and four patients with Paget's disease, and a mean of 1035 litres/day in 10 patients with Paget's disease after intravenous injection (Kanis and colleagues, 1982).4 The Miacalcin label, for calcitonin salmon, gives a terminal half-life of approximately 58 minutes after intramuscular and 59 to 64 minutes after subcutaneous administration.1 App's figureIn the half-life and pharmacokinetics table Time to peak ~1 h Reported in the sources Peak plasma levels of calcitonin salmon are reached "in approximately 23 minutes" after subcutaneous administration on the label;1 in six volunteers given human calcitonin 0.5 mg (Cibacalcin), the time of maximum concentration was 23.6 +/- 10 min after subcutaneous and 16.2 +/- 7.5 min after intradermal injection (Autret and colleagues, 1991).6 App's figureIn the half-life and pharmacokinetics table Bioavailability 70% Reported in the sources The label gives an absolute bioavailability of calcitonin salmon of approximately 66% after intramuscular and 71% after subcutaneous injection;1 a figure specific to human calcitonin was not found in the records retrieved. App's figureIn the half-life and pharmacokinetics table Route SubQ App's modelIn the half-life and pharmacokinetics part

Calcitonin is a peptide hormone, and the human form is a 32 amino acid peptide.2 Inzerillo and colleagues (Journal of Pediatric Endocrinology and Metabolism, 2004) write that calcitonin "was first reported as a hypocalcemic principle", with its origin later corrected to the parafollicular C-cells of the thyroid.2 The same review attributes its use in Paget's bone disease, osteoporosis, hypercalcaemia and osteogenesis imperfecta to its anti-resorptive effect.2 Xie and colleagues (International Journal of Endocrinology, 2020) write that human calcitonin was purified from patients with tumours of the thyroid C cells, which form calcitonin at very high levels.3

The app's entry is for human calcitonin, but most label information comes from calcitonin salmon, which the Miacalcin label describes as having a greater potency per mg and a longer duration of action than calcitonins of mammalian origin.1 The Miacalcin label lists an initial US approval of 1975.1 Among the first 20 of 21 DailyMed labels returned for "calcitonin", the single-ingredient labels were for calcitonin salmon, and the only labels naming human calcitonin were homeopathic mixtures with several ingredients. The app grades the evidence for calcitonin as strong.

2

How it works

The Miacalcin label calls calcitonin salmon "a calcitonin receptor agonist" that "acts primarily on bone, but direct renal effects and actions on the gastro-intestinal tract are also recognized".1 On bone, the label says single injections of calcitonin salmon "caused a marked transient inhibition of the ongoing bone resorptive process", and that with prolonged use "there is a persistent, smaller decrease in the rate of bone resorption".1 In the kidney, the label states that studies with injectable calcitonin salmon "show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption".1 The label adds that in healthy adults, who have a relatively low rate of bone resorption, calcitonin salmon "results in decreases in serum calcium within the limits of the normal range", and that decreases are "more pronounced" in healthy children and in patients whose bone resorption is more rapid.1 Xie and colleagues review early work in dogs, in which "hypercalcemia causes the production of a hormone which reduces the blood calcium level", and they say a clinical study showed calcitonin "directly suppressed the bone resorption and collagen breakdown" by reducing urinary hydroxyproline excretion.3 The app's entry describes the hormone as opposing parathyroid hormone; the sources used here describe parathyroid hormone as the hormone released "at a low level of calcium" to restore calcium to its standard range.3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~1 h
Bioavailability
70%
Typical dose
100–200 IU/day
Route
SubQ
Time to peak
~1 h

The second column of the table holds the app's own figures, shown beside what the sources report; the label figures are for calcitonin salmon, because no single-ingredient human calcitonin label was seen among the 20 of 21 DailyMed records shown.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~1 hFor human calcitonin given by intravenous infusion to eight healthy subjects, elimination was biphasic, with half-lives of 10.2 and 37.8 minutes (Antonin and colleagues, 1992).5 Other records retrieved for human calcitonin report clearance: metabolic clearance rates of 531 to 1224 litres/day on infusion in 12 normal subjects and four patients with Paget's disease, and a mean of 1035 litres/day in 10 patients with Paget's disease after intravenous injection (Kanis and colleagues, 1982).4 The Miacalcin label, for calcitonin salmon, gives a terminal half-life of approximately 58 minutes after intramuscular and 59 to 64 minutes after subcutaneous administration.1
Bioavailability70%The label gives an absolute bioavailability of calcitonin salmon of approximately 66% after intramuscular and 71% after subcutaneous injection;1 a figure specific to human calcitonin was not found in the records retrieved.
Time to peak~1 hPeak plasma levels of calcitonin salmon are reached "in approximately 23 minutes" after subcutaneous administration on the label;1 in six volunteers given human calcitonin 0.5 mg (Cibacalcin), the time of maximum concentration was 23.6 +/- 10 min after subcutaneous and 16.2 +/- 7.5 min after intradermal injection (Autret and colleagues, 1991).6
Volume of distributionNot givenThe label gives an apparent volume of distribution of calcitonin salmon of 0.15 to 0.3 L/kg.1
Duration of effect8 hIn four open-label trials of calcitonin salmon in hypercalcemia, serum calcium reduction "was evident within 1 to 2 hours", the peak effect "occurred within 24 to 48 hours", and dosing every 12 hours "maintained a hypocalcemic effect for approximately 5 to 8 days", the time period evaluated for most patients in the clinical trials.1

Kanis and colleagues also estimated the endogenous secretion rate of calcitonin in normal subjects at a mean of 124 +/- SEM 24 microgram/day.4 The records retrieved report no dosing interval for human calcitonin, so no level chart is drawn.

4

Human studies

The reports of human calcitonin retrieved from PubMed are from 1977 to 1991 and describe 13, 14, 6, 26 and 1 people; the label trials in the table are for calcitonin salmon.

Table 4.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Epstein and Owen, South African Medical Journal, 19777Single group of patients, each given the same course of human synthetic calcitonin; no comparison group is described13 patients with active Paget's disease of bone, 12 completing the course1 mg daily subcutaneously or intramuscularly for the first month, then 3 times per week for 5 monthsPlasma alkaline phosphatase fell by a mean of 31% and urinary hydroxyproline by 46% after 6 months; 10 of 12 patients derived moderate to great symptomatic improvement; side effects generally mild and self-limiting, flushing the most common
Altman and Collins-Yudiskas, Archives of Internal Medicine, 19878Treatment series in patients who had shown resistance to other agents; no comparison group is described14 patients with symptomatic, active Paget's disease resistant to parenteral synthetic salmon calcitonin, oral etidronate, or bothParenteral synthetic human calcitonin; follow-up of up to five years11 patients (79%) showed clinical and chemical improvement for up to five years; two received additional benefit with etidronate added
Autret and colleagues, Therapie, 19916Randomized comparison of intradermal and subcutaneous routes, each volunteer receiving both in random order, 8 days apart6 volunteers aged 18 to 40 years0.5 mg human calcitonin (Cibacalcin), single dose by each route; samples to 12 hoursTime of maximum concentration 23.6 +/- 10 min subcutaneous and 16.2 +/- 7.5 min intradermal; Cmax significantly higher with the intradermal route, while mean plasma levels and areas under the curve were not significantly different; mean fall in calcemia 0.29 +/- 0.21 and 0.18 +/- 0.11 mmol/l respectively; 16 mild side effects in 4 subjects
Kanis and colleagues, Clinical Science, 19824Clearance measurement by infusion or intravenous injection of synthetic human calcitonin; no comparator12 normal subjects and 4 patients with Paget's disease (infusion); 10 further patients with Paget's disease (injection)Infusion of 15-40 microgram/h for 2-24 h; injection of 0.5-1.0 mg intravenouslyMetabolic clearance rate 531 to 1224 litres/day on infusion; mean 1035 litres/day after injection; endogenous secretion rate in normal subjects a mean of 124 +/- SEM 24 microgram/day
Dietrich and colleagues, Acta Endocrinologica, 19799Single case reportOne 69-year-old woman with Paget's diseaseHuman calcitonin and the diphosphonate EHDP for 16 monthsLow-titre antibodies to human calcitonin, highest between 10 and 18 months and later no longer measurable
Label trials of calcitonin salmon injection in hypercalcemia (Miacalcin label)1Four open-label trials; patients' pre-therapy serum calcium used as control53 patients with carcinoma, multiple myeloma or primary hyperparathyroidism (lesser response)Calcitonin salmon every 12 hours; 5 to 8 days evaluated for most patientsAverage reduction of 8-hour post-injection serum calcium approximately 9% (2 to 3 mg/dL)
Label trials of calcitonin salmon injection in postmenopausal osteoporosis (Miacalcin label)1Two randomized, open-label, 2-year studies against controlPostmenopausal women 50 to 74 years of age; 34 on calcitonin salmon and 35 control in the combined fracture count100 International Units daily subcutaneously or intramuscularly, plus calcium and vitamin DNew vertebral compression fractures in year 1: 6 on calcitonin salmon and 5 control; in year 2: 7 in each group; total body calcium rose at 1 year, followed by a trend to decreasing total body calcium (still above baseline) at 2 years; the label states fracture reduction efficacy has not been demonstrated

Deeper analysis: Epstein and Owen, human synthetic calcitonin in Paget's disease (1977)

Epstein and Owen studied 13 patients with active Paget's disease of bone, "confirmed biochemically and radiologically", and 12 completed the course.7 The dose was 1 mg daily subcutaneously or intramuscularly for the first month and then 3 times per week for 5 months.7 The measured outcomes were symptoms, plasma alkaline phosphatase and urinary hydroxyproline.7 Ten of the 12 patients had "moderate to great symptomatic improvement", usually evident 6 weeks after the start, and in 4 patients the improvement "persisted" from 6 months to 1 year after treatment was stopped.7 Side effects were "generally mild and self-limiting, with flushing being the most common".7 The authors conclude that "human calcitonin is beneficial in the treatment of Paget's disease of bone" and that it may avoid the antibody resistance and allergic phenomena seen with other calcitonin preparations.7 The PubMed record describes a single group of patients with no comparison group, and gives no funding statement, author ties to a sponsor, or stated limitations.

Deeper analysis: Altman and Collins-Yudiskas, refractory Paget's disease (1987)

Altman and Collins-Yudiskas treated 14 patients with symptomatic, active Paget's disease who had "demonstrated resistance" to parenteral synthetic salmon calcitonin, oral disodium etidronate, or both in combination, using parenteral synthetic human calcitonin.8 Eleven patients (79%) "demonstrated clinical and chemical improvement for up to five years", and two patients "received additional benefit" with etidronate disodium added.8 The PubMed record does not describe the other three patients, a comparison group, the dose, funding, author ties to a sponsor or limitations.

Deeper analysis: Autret and colleagues, intradermal against subcutaneous human calcitonin (1991)

Autret and colleagues, from the clinical pharmacology department at the university hospital in Tours, gave 6 volunteers aged 18 to 40 calcitonin 0.5 mg (Cibacalcin, Ciba-Geigy Laboratory) by intradermal and subcutaneous routes in random order at the same injection site, with each administration spaced by 8 days.6 Plasma levels were measured by radioimmunoassay before administration and up to 12 hours afterwards.6 The maximum concentration was higher by the intradermal route ("Cmax is significantly higher with ID route"), while mean levels and areas under the curve over 0 to 1,440 min and 0 to 480 min were not significantly different between routes.6 The mean lowering of calcemia was 0.29 +/- 0.21 mmol/l after subcutaneous and 0.18 +/- 0.11 mmol/l after intradermal injection.6 There were "16 mild side effects (8 with each administration)" in 4 subjects, appearing before 5 min and "transient (1 hour)" for cutaneous manifestations, and between hours 3 and 7 for nausea and vomiting or asthenia.6 The PubMed record names the product but not a funder, lists no author ties to a sponsor, and states no limitations; the sample was six volunteers.6

Deeper analysis: Kanis and colleagues, clearance and endogenous secretion (1982)

Kanis and colleagues measured the metabolic clearance rate of human calcitonin in 12 normal subjects and four patients with Paget's disease by infusion of synthetic human calcitonin (15-40 microgram/h for 2-24 h), and in 10 further patients with Paget's disease from the disappearance of immunoreactive calcitonin after intravenous injection of 0.5-1.0 mg.4 The infusion range was 531-1224 litres/day and the injection mean 1035 litres/day (range 593-1408).4 They conclude that the endogenous secretion rate is low in normal subjects (mean 124 +/- SEM 24 microgram/day).4 The PubMed record gives the publication type as "Research Support, Non-U.S. Gov't", reports no half-life, and states no limitations or author ties to a sponsor.4

Deeper analysis: label trials of calcitonin salmon injection

The Miacalcin label states that in its Paget's disease trials, "open-label clinical trials of several months to two years duration with historical controls", biochemical abnormalities improved by more than 30% in about 2/3 of patients studied and bone pain improved in a similar fraction.1 For postmenopausal osteoporosis the label states that "Fracture reduction efficacy has not been demonstrated" and that the evidence of efficacy "is based on increases in total body calcium observed in clinical trials".1 The label summaries do not name the trials' investigators or funders.

5

Doses reported in studies and on labels

The app's typical dose is 100–200 IU/day; the reports below are in mass units for human calcitonin and in USP or International Units for calcitonin salmon.

Table 5.1Doses reported in studies and on labels7 rows
SourceCompound and routeDose reportedSetting
Epstein and Owen, 19777Human synthetic calcitonin, subcutaneous or intramuscular1 mg daily for the first month, then 3 times per week for 5 months13 patients with active Paget's disease
Autret and colleagues, 19916Human calcitonin (Cibacalcin), subcutaneous and intradermal0.5 mg single dose by each route6 volunteers aged 18 to 40
Kanis and colleagues, 19824Synthetic human calcitonin, intravenousInfusion of 15-40 microgram/h for 2-24 h; injection of 0.5-1.0 mgClearance measurement in 12 normal subjects and 14 patients with Paget's disease
Miacalcin label, Paget's disease1Calcitonin salmon, subcutaneous or intramuscular100 USP Units (0.5 mL) per daySymptomatic Paget's disease of bone, moderate to severe
Miacalcin label, hypercalcemia1Calcitonin salmon, subcutaneous or intramuscularStarting dose 4 USP Units/kg every 12 hours, increased to 8 USP Units/kg every 12 hours, to a maximum of 8 USP Units/kg every 6 hoursEarly treatment of hypercalcemic emergencies, alongside other agents
Miacalcin label, postmenopausal osteoporosis1Calcitonin salmon, subcutaneous or intramuscular100 USP Units (0.5 mL) per dayWomen greater than 5 years postmenopause; the label states the minimum effective dose for preventing vertebral bone mineral density loss has not been established
Xie and colleagues review, 20203Calcitonin salmon (reviewed nasal spray study)Daily dose of calcitonin 200 IUPostmenopausal osteoporotic women; the review says the findings were challenged mainly because of the elevated dropout rate (59 percent), and that a more significant higher dose is described as ineffective

Human calcitonin: Epstein and Owen describe side effects as "generally mild and self-limiting, with flushing being the most common", and Autret and colleagues recorded 16 mild side effects in 4 of 6 volunteers after single doses.7,6 Dietrich and colleagues describe low-titre antibodies to human calcitonin in one woman, call formation of such antibodies in man "a very rare event", and note that synthetic salmon calcitonin "induces an immune response in a high percentage (up to 78%) of the patients treated".9 The same report says there was "no immunological response to a single re-injection of hCT 14 months after discontinuation of therapy".9

Calcitonin salmon injection (Miacalcin label): the most common adverse reactions are "nausea with or without vomiting (10%), injection site inflammation (10%), and flushing of the face or hands (2% to 5%)".1 The label says the safety of the injection was assessed in open-label trials several months to two years in duration, and that nausea "is most evident when treatment is first initiated and tends to decrease or disappear with continued administration".1 It reports hypocalcemia "associated with tetany (i.e., muscle cramps, twitching) and seizure activity", and serious hypersensitivity reactions including "anaphylactic shock, and death due to anaphylaxis".1 It also reports circulating antibodies to calcitonin salmon and coarse granular casts in the urine sediment of young adult volunteers at bed rest, where "the urine sediment normalized after calcitonin salmon was stopped".1 In a meta-analysis of 21 randomized trials of calcitonin salmon by nasal spray or investigational oral formulations (10883 patients, 6 months to 5 years), malignancies were reported in 254/6151 (4.1%) on calcitonin salmon and 137/4732 (2.9%) on placebo.1 The label adds that the increased malignancy risk seen with the meta-analysis "was heavily influenced by a single large 5-year trial".1 The label states that "a definitive causal relationship between calcitonin salmon use and malignancies cannot be established from this meta-analysis", that the injection routes were not investigated in it, and that "A mechanism for these observations has not been identified".1 The label notes that concomitant use of calcitonin salmon and lithium "may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium".1 In rats, the label reports an increased incidence of pituitary adenomas after subcutaneous calcitonin salmon, and says "The significance of this finding to humans is unknown".1

7

Bloodwork and markers

The app lists calcium as the marker to monitor. The Miacalcin label states that hypocalcemia "must be corrected before initiating therapy" and lists reported hypocalcemia with tetany and seizure activity as a warning for calcitonin salmon.1 In the label hypercalcemia trials, the average reduction of 8-hour post-injection serum calcium was approximately 9% (2 to 3 mg/dL), and "Patients with higher values of serum calcium tended to show greater reductions".1 In the human calcitonin volunteer study, mean calcemia fell by 0.29 +/- 0.21 mmol/l after a subcutaneous 0.5 mg dose.6

Drugs@FDA lists the marketing status of Cibacalcin, a human calcitonin injection that FDA approved in 1986 under NDA 018470, as discontinued, so Cibacalcin is no longer marketed in the US.10 The Miacalcin label for calcitonin salmon injection lists indications for symptomatic Paget's disease of bone in patients with moderate to severe disease, early treatment of hypercalcemic emergencies, and postmenopausal osteoporosis in women greater than 5 years postmenopause.1 For Paget's disease the label adds that "There is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients" and limits use of the injection to "patients who do not respond to alternative treatments or for whom such treatments are not suitable"; for postmenopausal osteoporosis it says the injection is "reserved for patients for whom alternative treatments are not suitable".1 The 2026 WADA Prohibited List does not name calcitonin; the saved text of the list returned no match for "calcitonin".11 Its class S2 (peptide hormones, growth factors, related substances, and mimetics) states that "The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited", so the absence of a name is not a ruling on calcitonin either way.11

9

Storage and handling

Sources in this part

  1. 1Mylan Institutional

The Miacalcin label for calcitonin salmon injection states "Store in a refrigerator between 2° to 8°C (36° to 46°F)".1 It adds "Protect from freezing."1

10

What is not known

Sources in this part

  1. 5Antonin et al., 1992

The only half-lives of human calcitonin in people in the records retrieved come from one intravenous infusion study in eight healthy subjects; the other human measurements are clearance rates and time to maximum concentration, and the label half-life is for calcitonin salmon.5 A controlled trial of human calcitonin with a placebo or active comparator group was not identified in the 20 of 71 PubMed records examined for Paget's disease, and the reports described above enrolled 1 to 26 people and, apart from the six-volunteer route comparison, describe no comparison group. The app's entry says the human form is "substantially WEAKER" and shorter-acting than the salmon form; the sources here support a lower potency per mg for the human form (the label and review quoted above) but give no numerical comparison. Whether the app's bioavailability of 70% and its dose range in IU/day describe human calcitonin is not stated by the sources retrieved, which give 71% for subcutaneous calcitonin salmon and mass doses (0.5 to 1 mg) for human calcitonin.

What is the half-life of calcitonin?

The app lists a half-life of 1 hour for calcitonin, and the Miacalcin label gives a terminal half-life for calcitonin salmon of approximately 58 minutes after intramuscular and 59 to 64 minutes after subcutaneous administration.1 For human calcitonin given by intravenous infusion to eight healthy subjects, Antonin and colleagues report two elimination half-lives, 10.2 and 37.8 minutes, and Kanis and colleagues report clearance of 531 to 1224 litres/day on infusion.5,4

How long does calcitonin take to reach its peak level?

The app lists about 1 hour, and the Miacalcin label gives approximately 23 minutes for calcitonin salmon after subcutaneous administration.1 In six volunteers given human calcitonin 0.5 mg, the time of maximum concentration was 23.6 +/- 10 min after subcutaneous injection.6

What is the bioavailability of calcitonin?

The app lists 70%, and the Miacalcin label gives approximately 71% for calcitonin salmon after subcutaneous injection and 66% after intramuscular injection.1

Is human calcitonin the same as salmon calcitonin?

They are different peptides, and the Miacalcin label states that calcitonin salmon has a greater potency per mg and a longer duration of action than calcitonins of mammalian origin.1 Xie and colleagues write that "sCT potency is higher than that of hCT".3

Does calcitonin lower blood calcium?

In the label trials of calcitonin salmon in hypercalcemia the average reduction of 8-hour post-injection serum calcium was approximately 9% (2 to 3 mg/dL).1 In healthy adults the label says calcitonin salmon produces decreases in serum calcium "within the limits of the normal range".1

Is calcitonin banned by WADA?

Calcitonin is not named in the saved text of the 2026 WADA Prohibited List, which returned 0 matches for "calcitonin".11 The list's S2 class also covers "other substances with similar chemical structure or similar biological effect(s)", so the list text alone does not settle the question.11

What side effects have been reported with calcitonin?

For calcitonin salmon injection the label gives nausea with or without vomiting (10%), injection site inflammation (10%) and flushing of the face or hands (2% to 5%) as the most common adverse reactions.1 For human calcitonin, Epstein and Owen report side effects "generally mild and self-limiting, with flushing being the most common" in 13 patients with Paget's disease.7

Which blood marker does the app list for calcitonin?

The app lists calcium. The Miacalcin label reports hypocalcemia with tetany and seizure activity with calcitonin salmon injection.1

Has human calcitonin been studied in people?

Human calcitonin has been reported in studies in people, including 13 patients with Paget's disease (Epstein and Owen, 1977) and 14 patients with Paget's disease resistant to other agents (Altman and Collins-Yudiskas, 1987).7,8 Neither report describes a comparison group.

13

References

  1. Mylan Institutional. Miacalcin (calcitonin salmon) injection, solution. US prescribing information, DailyMed record, version 5. DailyMed label (calcitonin salmon)
  2. Inzerillo AM, Zaidi M, Huang CL. Calcitonin: physiological actions and clinical applications. J Pediatr Endocrinol Metab 2004. PMID 15301040
  3. Xie J, et al. Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations. Int J Endocrinol 2020. PMC7501564
  4. Kanis JA, et al. An estimate of the endogenous secretion rate of calcitonin in man. Clin Sci (Lond) 1982. PMID 7083775
  5. Antonin KH, et al. Colonic absorption of human calcitonin in man. Clin Sci (Lond) 1992. PMID 1335402
  6. Autret E, et al. Comparison of plasma concentration and tolerance of a single dose of human calcitonin by intradermal and subcutaneous administration. Therapie 1991. PMID 2020925
  7. Epstein S, Owen G. Paget's disease of bone (osteitis deformans) treated with human synthetic calcitonin. S Afr Med J 1977. PMID 850845
  8. Altman RD, Collins-Yudiskas B. Synthetic human calcitonin in refractory Paget's disease of bone. Arch Intern Med 1987. PMID 3111398
  9. Dietrich FM, Fischer JA, Bijvoet OL. Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease. Acta Endocrinol (Copenh) 1979. PMID 517048
  10. US Food and Drug Administration. Drugs@FDA: NDA 018470, Cibacalcin (calcitonin human). Read 19 November 2026. Drugs@FDA
  11. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list